Merrimack Sells Pancreatic Cancer Drug to Ipsen for $1 Billion

Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen.
Author:
Publish date:

Merrimack Pharmaceuticals' (MACK) - Get Report  shares soared 43% in pre-market trading to $5.16 as news broke the company sold its pancreatic-cancer treatment Onivyde to French drugmaker Ipsen (IPSEY) .

This article was written by a staff member of TheStreet.